Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the safety and tolerability of PVX-410, (a cancer vaccine), treatment regimen for patients with smoldering multiple myeloma as a single agent and in combination with lenalidomide.

Clinical Trial Description

This is a dose escalation, phase 1/2a study to assess the safety and tolerability of PVX-410, (a multi-peptide cancer vaccine), treatment regimen in patients with smoldering multiple myeloma as a single agent and in combination with lenalidomide.. Approximately 22 patients will receive six (6) bi-weekly, subcutaneous injections of PVX-410 for a total of twelve (12) weeks of treatment. Safety will be monitored throughout the study. Tolerability, immunogenicity and clinical response will also be measured as described in the protocol. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01718899
Study type	Interventional
Source	OncoPep, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	November 2012
Completion date	September 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01222286` - Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma	Phase 2
Withdrawn	`NCT00503763` - Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma	Phase 2
Active, not recruiting	`NCT02916771` - Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma	Phase 2
Completed	`NCT01955395` - Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma	N/A
Completed	`NCT01237054` - Imaging in MGUS, SMM and MM	Phase 2
Completed	`NCT02903381` - A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma	Phase 2
Active, not recruiting	`NCT03301220` - A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma	Phase 3
Active, not recruiting	`NCT03236428` - Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma	Phase 2
Completed	`NCT00112827` - Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma	Phase 1/Phase 2
Completed	`NCT00099047` - Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma	Phase 2
Terminated	`NCT01248455` - A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma	Phase 2
Active, not recruiting	`NCT03289299` - Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant	Phase 2
Not yet recruiting	`NCT06365060` - Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Active, not recruiting	`NCT02415413` - Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma	Phase 2
Completed	`NCT01302886` - Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma	Phase 2
Recruiting	`NCT05841550` - The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma	Phase 1/Phase 2
Recruiting	`NCT06183489` - Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma	Phase 2
Recruiting	`NCT06383143` - Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Active, not recruiting	`NCT02886065` - A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM	Phase 1
Withdrawn	`NCT01571726` - Imaging Studies and the Development of Multiple Myeloma	Phase 2